|  |
| --- |
| **SWGLH – Cancer Genomics Test Request Form****Solid Tumour and Lymphoid Pathology – Adult** (non-sarcoma)Please complete electronically: type or click in the grey boxes, send this request to the appropriate Histopathology laboratory as soon as possible. |

|  |
| --- |
| **Patient Details**: Paste patient demographics here or fill in fields below: |

|  |  |
| --- | --- |
| Patient name:       | Referring Consultant:       |
| Address:      Postcode:       | Department and Hospital:       |
| Report destination (email):           |
| DOB:       | Sex:       | Pathologist:       |
| NHS number:       | Date of resection/biopsy:       |
| Pathology block number:       | Date test requested:       |
| Hospital number:       | Date sample sent to SW GLH:       |

|  |
| --- |
| **Clinical summary:**       |
|  |
| **Genomic tests** (please click in the appropriate boxes below to make your selection). Please refer to the National Genomics Test Directory for Cancer: <https://www.england.nhs.uk/publication/national-genomic-test-directories/>

| **Code** | **Clinical Indication** | **Test Code**  | **Test Name** | **Extraction/method** **(see sample requirements\*)** |
| --- | --- | --- | --- | --- |
|  |  | [ ]  | Test not on form (please specify test required above) | DNA + RNA |
| M1 | Colorectal Carcinoma | M1.1[ ]  | Small variants (*KRAS, NRAS, BRAF*) | DNA |
|  |  | M1.4[ ]  | MSI Testing (+/- *BRAF*/*MLH1* as per Lynch pathway) | DNA |
|  |  | M1.1[ ]  | *BRAF* ddPCR (for MSI-High/MMR deficient tumours) | DNA |
|  |  | M1.5[ ]  | *MLH1* promoter hypermethylation (for MSI-High/MMR deficient, *BRAF* V600 wild type tumours) | DNA |
| M2 | Ovarian Carcinoma | M2.1[ ]  | Small variants (*BRCA1*, *BRCA2*) | DNA |
|  |  | M2.2[ ]  | Small variants (*SMARCA4*) | DNA |
|  |  | M2.4[ ]  | 1HRD analysis **and** *BRCA1/2* (1st line) | **10 x 5µm slide mounted sections along with H&E with >30% neoplastic cells highlighted.**  |
| M245 | Ovarian sex cord stromal tumour | M245.1[ ]  | Small variants (*APC, CTNNB1, DICER1, FOXL2*) | DNA |
| M215 | Endometrial Cancer | M215.2[ ]  | *MLH1* promoter hypermethylation (for samples with loss of MLH1/PMS2 by IHC) | DNA |
|  |  | M215.5[ ]  | Small variants (*POLE, ARID1A*) | DNA |
| M217 | Bladder Cancer | M217.1 [ ]  | Small variants (*FGFR3, FGFR2*) | DNA |
|  |  | M217.3 [ ]  | *FGFR3, FGFR2, NTRK1, NTRK2, NTRK3* gene fusion | RNA |
| M218 | Prostate Cancer | M218.1 [ ]  | Small variants (*BRCA1, BRCA2, ATM, CDK12*) | DNA |
|  |  | M218.2[ ]  | *TMPRSS2-ERG, NTRK1, NTRK2, NTRK3* gene fusion | RNA |
| M219 | Pancreatic Cancer | M219.1 [ ]  | Small variants (*BRCA1, BRCA2*) | DNA |
|  |  | M219.5 [ ]  | MSI testing | DNA |
| M220 | Cholangiocarcinoma | M220.4[ ]  | *FGFR2, NTRK1, NTRK2, NTRK3* fusion analysis | RNA |
|  |  | M220.5[ ]   | MSI testing | DNA |
|  |  | M220.6[ ]  | Small variants *(IDH1)* | DNA |
| M221 | Spitzoid Tumour | M221.1[ ]  | *NTRK1, NTRK2, NTRK3* fusion analysis | RNA |
| M227 | Any Solid Tumour | M227.1[ ]  | *NTRK1, NTRK2, NTRK3* fusion analysis  | RNA |
|  |  | M227.3 | 5-Fluorouracil Toxicity DPYD analysis | [**Complete Core Form**](https://www.nbt.nhs.uk/sites/default/files/document/GMS%20Simple%20Test%20Request%20Form.pdf)(blood sample required) |
| M236 | Oesophageal Cancer | M236.1[ ]  | MSI testing | DNA |
| M237 | Gastric Cancer | M237.1[ ]  | MSI testing | DNA |
| M238 | Small Bowel Cancer | M238.1[ ]  | MSI testing | DNA |
| M3 | Breast Cancer | M3.6[ ]  | Small variants (*PIK3CA*) | DNA |
| M4 | Non-Small Cell Lung Cancer | M4.1 M4.2[ ]  | *EGFR, ALK, BRAF, KRAS, MET, ERBB2* small variants, plus *ROS1, ALK, RET, NRG1, NTRK1, NTRK2, NTRK3* fusions | DNA and RNA |
|  |  | M4.5 | *EGFR* hotspot ctDNA | Complete[**ctDNA referral form**](https://www.nbt.nhs.uk/sites/default/files/SWGLH%20ctDNA%20Request%20Form_0.doc) |
| M7 | Melanoma - Adult | M7.1[ ]  | Small variants (*BRAF, KIT, NRAS*) | DNA |
| M187 | Uveal melanoma | M187.3[ ]  | Small variants (*BRAF, KIT, NRAS, NF1, GNA11, GNAQ*) | DNA |
| M8 | Gastrointestinal Stromal Tumour | M8.1[ ]  | Small variant (*KIT, PDGFRA*) | DNA |
| M9 | Thyroid Papillary  | M9.1[ ]  | Small variants (*BRAF, KRAS, NRAS, HRAS, TERT*) | DNA |
|  | Carcinoma - Adult | M9.2[ ]  | *RET, NTRK1, NTRK2, NTRK3* gene fusion | RNA |
|  |  |  |  |  |
| M10 | Thyroid Follicular Carcinoma | M10.1[ ]  | Small variants (*KRAS, NRAS, HRAS*) | DNA |
|  |  | M10.2[ ]  | *RET, NTRK1, NTRK2, NTRK3* gene fusion | RNA |
| M11 | Poorly Differentiated  | M11.1[ ]  | Small variant (*TP53, BRAF*) | DNA |
|  | Anaplastic Thyroid Carcinoma | M11.4[ ]  | *RET, ALK, NTRK1, NTRK2, NTRK3* gene fusion | RNA |
| M12 | Thyroid Medullary  | M12.1[ ]  | Small variants (*RET*) | DNA |
|  | Carcinoma | M227.1[ ]  | *NTRK1*, *NTRK2*, *NTRK3* gene fusion | RNA |
| M13 | Phaeochromocytoma | M13.1[ ]  | Small variants (*RET*) | DNA |
| M14 | Adrenal Cortical Carcinoma | M14.1[ ]  | Small variants (*TP53*) | DNA |
| M15 | Head and Neck Squamous | M15.1[ ]  | Small variants (*CDKN2A, EGFR, TP53*) | DNA |
|  |  Cell Carcinoma | M15.2[ ]  | *RET, NTRK1, NTRK2, NTRK3* gene fusion | RNA |
| M16 | Adenoid Cystic Carcinoma | M16.2[ ]  | *MYB*-*NFIB*, *NTRK1*, *NTRK2*, *NTRK3* gene fusion | RNA |
| M18 | Renal Cell Carcinoma | M18.6[ ]  | *TFE3, NTRK1, NTRK2, NTRK3* gene fusion  | RNA |
|  |  | M18.2 [ ]  | Small Variants (*BRAF, ELOC,FH, MET, MTOR, SDHA, SDHB, SDHC, SDHD, TSC1, TSC2, VHL*) | DNA |
| M5 | Mesothelioma | M5.1[ ]  | Copy number variant *CDKN2A* | FISH |
| M6 | Mucoepidermoid Carcinoma |  | *MAML2, NTRK1, NTRK2, NTRK3* gene fusion | RNA |
|  |  | M6.2 [ ]  |  |  |

|  |  |  |  |
| --- | --- | --- | --- |
| **Lymphoreticular Pathology:** |  | Lymphoid NGS Panels (specify): | DNA |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| M95 | B-cell NHL | M95.1 [ ]  | *B-cell Clonality* | DNA |
| M111 | T-cell NHL | M111.2[ ]  | *T-cell Clonality* | DNA |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| FISH(1) |   |       | FISH(2)  |       |

**Inherited cancer tissue analysis requests:** For testing where no living affected individual is available to test but tumour or normal material is available from a deceased individual.**Clinical Genetics referrals only**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| R208 | Inherited breast cancer and ovarian cancer | R208.1[ ]  | Small variant  | **Clinical Genetics to fill in****If available, please cut the following:** |
| R207 | Inherited ovarian cancer (without breast cancer) | R207.1[ ]  | Small variant  | [ ]  **Tumour tissue (DNA)**[ ]  **Normal tissue (DNA)** |
|  |  |  |  |  |
| M1.9 | Inherited MMR deficiency (Lynch syndrome) | M1.9[ ]  | Small variant  | **Histopathology to fill in** |
| R211 | Inherited polyposis and early onset colorectal cancer | R211.1[ ]  | Small variant  | **Sample sent:**[ ]  **Tumour tissue (DNA)** |
|  |  |  |  | [ ]  **Normal tissue (DNA)** |

 |
| **\*Sample Requirements:****Tumour DNA and/or RNA extraction**[ ]  Sample with >**20%** neoplastic cells: send one tube (Eppendorf or Universal): containing 5 x 10µm sections (curls/scrolls) OR[ ]  Sample with **<20%** neoplastic cells: send 10 x 5µm slide mounted sections along with H&E with region/s of >20% neoplastic cells circled to enable macro-dissection and extraction of sample with >20% neoplastic cellsNB. If two tests are required the same requirements apply, i.e. it is not necessary to send double the material.**Please indicate the percentage neoplastic cell content in the curls or the marked region of the H&E:**[ ]  <20% (not recommended due to risk of false negative result but please specify reason and neoplastic cell content if sending       )[ ]  20-30% [ ]  31-40% [ ]  41-50% [ ]  51-60% [ ]  61-70% [ ]  71-80% [ ]  81-90% [ ]  91-100%**FISH**[ ]  Please send 2 x 4µm and 2 x 2µm sections on 'APES' or 'sticky' slides **per test** required with an accompanying H&E slide with the appropriate tumour rich area(s) marked.**Normal tissue DNA extraction**[ ]  Send one tube (Eppendorf or Universal): containing 5 x 10µm sections (curls/scrolls)Please note that we are unable to receive blocks and require cut material to be sent as stipulated above.Please label **all** slides or tubes with three patient identifiers i.e. name, block number and date of birth. |
| **Any additional information or requests:**      **Histopathology Report**: (please include a copy of the histopathology report for this patient) [ ]  |
| **Samples should be dispatched as soon as possible as the patient’s treatment may be dependent upon the molecular analysis.****Send paperwork and sample to:** Bristol Genetics Laboratory, Pathology Sciences, Southmead Hospital, Bristol BS10 5NB**Phone:** 0117 414 6168 **Email:** **SWGLHcancer@nbt.nhs.uk*****CONSENT STATEMENT It is the referring clinician’s responsibility to ensure that the patient/carer knows the purpose of the test and that the DNA sample will be retained in long term storage and may be used for future diagnostic tests. Completing this form is an indication that the clinician has obtained consent for testing and storage. The patient should be advised that the sample may be used anonymously for quality assurance and training purposes. Please advise us of any restrictions.*** *1The HRD testing service is being offered as a Package Deal in accordance with clause 18.1 of the Association of the British Pharmaceutical Industry’s Code of Practice. The provision of this service is funded by global co-promotion agreement between AstraZeneca & MSD. The service is delivered in accordance with arrangements agreed with NHS England and NHS Improvement and facilitated by NHS Genomic Laboratory Hubs. The HRD test is performed by Myriad Genetics Inc. in the United States.* |